Table 2 Analysis of abatacept effectiveness overall, and stratified by line of therapy, and by number of previous failed anti-TNFs
Measure | Baseline | Change from baseline to month 6 | ||
|---|---|---|---|---|
N | Mean (SD) | Mean (95% CI) | ||
Overall | ||||
DAS28 (ESR) | 539 | 5.5 (1.2) | 473 | −1.5 (−1.6, –1.3) |
DAS28 (CRP) | 151 | 5.2 (1.3) | 113 | −1.5 (−1.7, –1.2) |
CDAI | 647 | 31.7 (13.2) | 605 | −15.2 (−16.3, –14.1) |
First-line | ||||
DAS28 (ESR) | 33 | 5.2 (1.2) | 29 | −1.7 (−2.3, –1.1) |
DAS28 (CRP) | 5 | 4.5 (1.3) | 4 | −2.0 (−3.2, –0.8) |
CDAI | 48 | 31.9 (11.9) | 41 | −18.3 (−22.0, –14.6) |
Second-line | ||||
DAS28 (ESR) | 506 | 5.6 (1.2) | 444 | −1.5 (−1.6, –1.3) |
DAS28 (CRP) | 146 | 5.3 (1.3) | 109 | −1.4 (−1.7, –1.2) |
CDAI | 599 | 31.7 (13.2) | 564 | −15.0 (−16.1, –13.9) |
One previous anti-TNF | ||||
DAS28 (ESR) | 247 | 5.5 (1.2) | 221 | −1.6 (−1.8, –1.4) |
DAS28 (CRP) | 64 | 5.2 (1.3) | 46 | −1.7 (−2.2, –1.2) |
CDAI | 291 | 30.6 (12.7) | 278 | −15.0 (−16.5, –13.5) |
≥2 previous anti-TNFs | ||||
DAS28 (ESR) | 251 | 5.6 (1.3) | 216 | −1.3 (−1.5, –1.1) |
DAS28 (CRP) | 78 | 5.3 (1.4) | 59 | −1.2 (−1.6, –0.8) |
CDAI | 295 | 32.5 (13.6) | 275 | −14.7 (−16.4, –12.9) |